A later menopause has been associated with a decreased cardiovascular risk but with an increased risk for breast and endometrial cancer. The net effect on mortality is unclear. We determined the association of age at menopause with longevity and with the balance between cardiovascular and cancer mortality. Methods: We analyzed data from a breast cancer screening cohort comprising 12,134 postmenopausal women followed for an average of 17 years. We used Cox proportional hazards models and life tables to calculate the life expectancy of an average Dutch woman at age 50. Results: During 204,024 person-years, there were 2607 deaths, of which 963 were due to cardiovascular diseases and 812 due to cancer. Ischemic heart disease risk decreased with a later menopause (hazard ratio ͓HR͔ ϭ 0.98 per year; 95% confidence interval ϭ 0.96 -0.99), but the risk of fatal uterine or ovarian cancer increased (1.07 per year; 1.01-1.12). A later menopause was associated with longer overall survival; HR for total mortality was 0.98 per year (0.97-0.99). Life expectancy in women with menopause after age 55 was 2.0 years longer than those with menopause before age 40. Adjustment for potential confounders did not materially change the results. Conclusions: Age-adjusted mortality is reduced 2% with each increasing year of age at menopause. In particular, ischemic heart disease mortality is 2% lower. Although the risk of death from uterine or ovarian cancer is increased by 5%, the net effect of a later menopause is an increased lifespan. (Epidemiology 2005;16: 556 -562) 
T he relation between late menopause and a reduced cardiovascular disease (CVD) risk is well established. 1, 2 Observational studies have shown a reduced risk of cardiovascular disease, [1] [2] [3] [4] fewer calcifications in the aorta 5 and less extensive atherosclerosis 6 in women with later menopause. Menopausal state has recently been added to the Framingham risk function for estimating absolute cardiovascular disease risk in women. 7 Also, fracture risk decreases when menopause occurs later. 8 In contrast, later menopause has been related to increased risk of breast cancer 9,10 endometrial and ovarian cancer, and perhaps hepatocellular cancer. [11] [12] [13] However, the risk of colorectal cancer appears decreased. 14 These malignancies are common in Western societies.
Most studies have reported on the relation between age at menopause and cause-specific mortality. Little is known about the net effect of age at menopause on life expectancy. The objective of the present study was to determine the association of age at menopause with longevity, and to determine the balance between cardiovascular and cancer mortality at different ages at menopause using longitudinal data from a large Dutch breast cancer screening cohort.
METHODS

Study Population
Between December 1974 and September 1977, 14,701 (72%) of the 20,555 women (age 48 -68 years) living in Utrecht were enrolled in the Diagnostisch Onderzoek Mammacarcinoom cohort as part of a breast cancer screening program. Study procedures have been described in more detail elsewhere. 15 Briefly, women were invited for several screening examinations, up to a maximum of 5. Information on smoking habits, medication and medical and reproductive history was collected through questionnaires. Information on age at menopause was missing for 982 women (7%) and these women were excluded from this analysis. Users of postmenopausal hormone replacement therapy (n ϭ 1588) were also excluded, leaving 12,134 women for the analyses.
Variables
Height and weight were measured at baseline and body mass index (BMI; kg/m 2 ) was calculated. We categorized menopause as (1) natural when menstrual bleeding had stopped spontaneously for at least 12 months, (2) due to hysterectomy when only the uterus was removed, (3) due to ovariectomy when the ovaries or the ovaries in combination with the uterus were removed, or (4) unknown. Hypertension was inferred from the reported use of antihypertensive medication. Similarly, women on oral antidiabetic drugs or insulin or a diabetes diet were classified as diabetic. Presence of cardiovascular disease was defined by self-reported use of medication for cardiovascular disease, including aminoglycosides, antiarrhythmic drugs, nitrates, other antianginal drugs, or anticoagulants. Oral contraceptive use was coded as "ever used" or "never used," because the number of women taking oral contraceptives was too small for detailed analysis. Parity and age at first delivery were combined in 1 variable with 3 categories: no children, children before or at the age of 24, and children after the age of 24. Data on smoking were collected at the second screening examination (1 year after the first examination) and are therefore not known for women who did not attend the second screening examination (n ϭ 2458).
Assessment of Mortality
The mean follow up Ϯ standard deviation (SD) was 17 Ϯ 5.1 years. There were 2607 deaths during 204,024 personyears; 963 were due to cardiovascular diseases, 812 were due to cancer, and 832 were due to other causes. At the end of follow up (1 January 1996), 1805 women (15%) had moved outside the area and 7722 women (64%) were still alive. Mortality follow up was more than 99% complete and women gave informed consent for participation. Approval was obtained from the Institutional Review Board of the University Medical Center Utrecht and women gave informed consent for participation.
The Utrecht Municipal Registry informed the investigators about places of residence and deaths of DOM-cohort members on a monthly basis. Causes of death were obtained from the woman's general practitioner and coded according to the ninth revision of the International Classification of Diseases (ICD-9). Codes of the various ICD classifications used for end point definition are presented in the Appendix (available with the electronic version of this article at www.epidem.com).
Data Analysis
Analyses were conducted for total mortality, cardiovascular mortality (ischemic heart disease mortality, cerebrovascular disease mortality, and mortality from stroke), and cancer mortality using Cox proportional hazard regression models. Death from other causes and loss to follow up due to moving outside Utrecht were considered censoring events.
Because mortality increases with age, all analyses were adjusted for age at entry. The association between age at menopause and mortality was analyzed with age at menopause as a continuous or as a categorized variable (Ͻ40, 40 -44, 45-49, 50 -54, or Ͼ55 years). Women with menopause between 50 and 54 years of age were taken as a reference category. Results are presented as hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs). To control for potential confounding, the following factors were entered in a multivariate Cox proportional hazards model, first 1 by 1 and then all factors simultaneously: year of birth, occurrence of natural menopause, parity, age at first delivery, past use of oral contraceptives, hypertension, BMI, smoking, diabetes mellitus, or previous CVD. To evaluate whether some risk factors modify the association of age at menopause and (cause-specific) mortality risk, we performed stratified analyses with obesity (BMI Ͻ30 or BMI Ն30), type of menopause (natural, hysterectomy, ovariectomy, unknown), age at entry (Յ55 or Ͼ55 years of age), and smoking (never, past, current Ͻ10/d, current 10 -20/d, current Ͼ20/d) as distinguishing variables.
To study the association of age at menopause with longevity, a life table was constructed using a hypothetical population of women age 50 years. First, we applied Dutch national mortality risks to this population to obtain an estimate of longevity. Second, we divided the mortality risks into 3 categories: cardiovascular mortality, cancer mortality, and other mortality, based on the cause-specific proportions observed in our study. Then we estimated, for each menopause category, the life expectancy using the cause-specific mortality risks multiplied by the observed hazard ratio in our analyses. Finally, we calculated the difference in life expectancy between women having menopause at 55 years of age or older and women with menopause before age 40.
RESULTS
Characteristics of the population are presented in Table  1 . Mean Ϯ SD age at menopause was 49.0 Ϯ 4.5 years (median 50 years); 78% of women had their menopause between 45 and 54 years of age. For never-smokers, mean age at menopause was 49.3 Ϯ 4.5 years (median 50 years), for past smokers 48.5 Ϯ 4.9 years (median 49 years), and for current smokers 48.5 Ϯ 4.6 years (median 49 years). When stratified by presence of obesity (BMI Ն30 kg/m 2 ), mean age at menopause was 48.9 Ϯ 4.8 years for obese women (median 50 years) and 49.0 Ϯ 4.5 years for nonobese women (median 50 years).
A later menopause was associated with an age-adjusted decreased total mortality risk ( As demonstrated in Tables 3 and 4 , the associations tended to be more pronounced for younger women. Hazard ratios for CVD tended to be lower in never-smoking women.
Type of menopause (natural menopause or not) did not affect the associations between age at menopause and cause-specific mortality.
The net effect of a later menopause is demonstrated in Figure 1 . Life expectancy in women with a very late menopause (Ͼ55 years) was 2.0 years longer compared with women who had an early menopause (Ͻ40 years) (adjusted for age differences at entry in the study).
DISCUSSION
In this prospective cohort study, a 1-year delay in menopause was associated with a 2% decreased risk of death from all causes. For cause-specific mortality, the most marked risk reductions were observed for ischemic heart disease (2%). The risk of death from uterine or ovarian cancer increased 7% with each year of delay in menopause. The associations were most pronounced among younger women and leaner women. The net effect of a later menopause was an increased lifespan.
The prospective design of this study makes biased reporting of age at menopause unlikely. 3 As demonstrated in previous reports, self-reported age at menopause and type of menopause are reasonably valid and reproducible. 16, 17 Smoking is a powerful risk factor for CVD and cancer, and is related to an earlier menopause. 18 The mean age at menopause among current smokers in our cohort was 48.6 years, compared with 49.4 for never-smokers, making smoking a serious potential confounder. Additional adjustment for smoking or exclusion of smokers left the results essentially unchanged, suggesting that residual confounding by smoking is unlikely. When stratified according to smoking behavior, the associations tended to be more pronounced among neversmokers than among current and past smokers, which provides additional support for this reasoning. Several other follow-up studies have reported an association between age at menopause and total mortality. 19 -21 Some of these studies were too small to explore causespecific mortality or effects of type of menopause. The present study largely confirms these findings and expands the available evidence by presenting precise estimates for causespecific mortality.
Most cohort studies have investigated the relation between age at menopause and the risk of specific diseases. A recent report from the Nurses' Health Study 4 included 35,616 women without CVD at baseline, with natural menopause, and with no history of hormone replacement therapy use. The risk of (nonfatal) coronary heart disease (CHD; adjusted for age and smoking) increased 3% per 1-year decrease in age at menopause, but risk of stroke was not affected. Both results are quite similar to our own. Their finding, however, was apparently confined to smoking women, in contrast to the results of our study. Other studies also support a cardioprotective effect of a later menopause. 3, [22] [23] [24] [25] [26] A stronger effect of age at menopause on CHD at younger ages (as we saw) has been reported by several other studies as well. 2, 3, 22 This pattern may be due to cessation of exposure to potentially cardioprotective endogenous estrogens longer ago in these women. These differences could also relate to differences in the distributions of age at menopause as well as the proportions with surgical versus natural menopause.
Some studies observed a U-shaped association, with an increased risk of CVD in women who had a very late menopause (Ͼ55 years). 19, 25 A few studies observed the increased risk of CHD after menopause to be stronger in or even restricted to women with a surgical menopause. 24, 26 Use of estrogens appeared to prevent this increased risk. 24 We did not confirm this finding in the present study. Most of the evidence regarding estrogens and cancer risk deals with exogenous estrogens and suggests an increased risk of (fatal) breast and endometrial cancer among hormone replacement therapy users. 27, 28 However, several studies indirectly provide support for an association between exposure to endogenous estrogens and an increased risk of breast cancer, endometrial cancer, and ovarian cancer. 10, 12 Women who subsequently developed breast cancer are reported to have 15% higher mean serum concentrations of estradiol compared with their control counterparts. 29 The magnitude of the increase in risk of breast cancer associated with each year of use of hormone replacement therapy appears to be roughly equivalent to the increase associated with delaying menopause by 1 year. 9 Our results indicate that, overall, women with a late menopause live 2 years longer than women with an early menopause. This difference is comparable to previous estimates 30 and, given the magnitude, may justify further studies on modifiable determinants of age at menopause. 
